Abstract:Pharmaceuticals are recognised among emerging contaminants, particularly in water. They have the potential to alter ecosystem dynamics, with notable examples including hormone-induced feminization of male fish and disruptions to oogenesis in invertebrates. To assess the risk posed by pharmaceuticals, it is essential to understand their amount (via Measured Environmental Concentrations MEC) and their actual effects on target species (via Predicted No Effect Concentrations PNEC). Recently, many studies have aimed to collect MEC data from around the world, but a comprehensive overview is still lacking. Thus, the objective of this study is to provide a comprehensive overview by examining recently published literature on MEC data for a wide range of pharmaceuticals. Additionally, to enable risk assessment, this study also reviewed the published literature on PNEC data and integrated it with existing databases. A total of 315 substances were selected for MEC data extraction, with the inclusion of 56 articles. The most frequently monitored locations were Cadiz Bay in Spain (90 samples), the River Thames in the UK (51), and Hrdějovice in the Czech Republic (49). Most MEC samples were collected from surface water (N=325), influent wastewater treatment plants (WWTP) (205), and effluent WWTP (118). Based on PNEC values, risk analysis identified 81 pharmaceuticals as high-risk, with the highest risk values for propranolol (risk quotient [RQ]: 29,450,000), diclofenac (395,920), and 17alpha-ethinylestradiol (95,946). Additionally, the ATC classes with the most high-risk substances were anti-infectives (J), nervous system agents (N), cardiovascular agents (C), antineoplastic agents (L), analgesics (M), and sex hormones (G). The findings of this study highlight the widespread impact of pharmaceuticals across the globe and the involvement of multiple therapeutic classes. To move beyond the current point-in-time overview, which is limited to specific locations and sampling periods, systems for continuous monitoring of pharmaceuticals should be developed. This could involve the creation of resource-efficient methods and the integration of sampling data with estimation models. Furthermore, these results could serve as a starting point for developing and implementing actions to prevent and mitigate the environmental impact of pharmaceuticals.

Environmental Hazard of anticancer drugs: State of the art and future perspective for marine organisms

Assessing the impact of antineoplastic drugs in the aquatic environment: State of the art and future perspective for freshwater organisms

Anticancer drugs in the aquatic ecosystem: Environmental occurrence, ecotoxicological effect and risk assessment

Anticancer drugs in surface waters: what can we say about the occurrence and environmental significance of cytotoxic, cytostatic and endocrine therapy drugs?

Marine Anticancer Agents: An Overview with a Particular Focus on Their Chemical Classes

Human pharmaceuticals in the marine environment: Focus on exposure and biological effects in animal species

New insights on cytostatic drug risk assessment in aquatic environments based on measured concentrations in surface waters

Contributions towards the hazard evaluation of two widely used cytostatic drugs

From Marine Origin to Therapeutics: The Antitumor Potential of Marine Algae-Derived Compounds

Are cytostatic drugs in surface waters a potential threat?

Recent Advancement in Anticancer Compounds from Marine Organisms: Approval, Use and Bioinformatic Approaches to Predict New Targets

Treatment-driven removal efficiency, product formation, and toxicity evolution of antineoplastic agents: Current status and implications for water safety assessment

Predicted concentrations of antineoplastic drugs in the aquatic environment: The case of Ría de Vigo (NW, Spain)

From Seabed to Bedside: A Review on Promising Marine Anticancer Compounds

Hazard assessment of antineoplastic drugs and metabolites using cytotoxicity and genotoxicity assays

Antineoplastic compounds in the environment—substances of special concern

The Dark Side of Platinum Based Cytostatic Drugs: From Detection to Removal

Marine-Derived Anticancer Agents: Clinical Benefits, Innovative Mechanisms, and New Targets

Bioaccumulation and biomagnification potential of pharmaceuticals with a focus to the aquatic environment

The environmental impact of pharmaceuticals: an evidence-mapping review of recent data on aquatic concentrations and predictable effects

Emerging Estrogenic Pollutants in the Aquatic Environment and Breast Cancer